CannabisNewsVideos

VIDEO: Cannabics Pharmaceuticals (OTCMKTS:CNBX) Cannabis Cancer Diagnostics

MidasLetter Live
|

Cannabics Pharmaceuticals (OTCMKTS:CNBX) CEO Eyal Barad discusses the company’s plans to collect data on cannabinoids and cancer to create diagnostic tools and treatments for the disease. Barad sees Cannabics’ data as especially useful for doctors who prescribe cannabis therapies to cancer patients. Cannabics plans to further commercialize its diagnostic testing products and develop additional palliative products for the cancer market. Cannabics intends to test its products and collect data in Israel, the United States, and Germany, but remains interested in the Canadian medical cannabis market.

Transcript:

James West:   Eyal!

Eyal Barad:   Hi, how are you doing?

James West:   Fantastic, how are you doing?

Eyal Barad:     Good, James, how’s it going?

James West:   Eyal, are you on a laptop? Yeah, there we go.

Eyal Barad:   I’m actually on my phone out here in Israel. It’s almost 11:00 p.m., talking to you. how you guys doing?

James West:   Fantastic.

Ed Milewski:  Nice to meet you.

James West:   We’re curious about your company, Cannabics Pharmaceuticals.

Eyal Barad:   Yeah. What can I tell you about it?

James West:   Well, you’ve got two new scientists to further develop cannabinoid diagnostic tests for treatments of cancer?

Eyal Barad:   Yeah. Cannabics Pharmaceuticals has been around for about four or five years. We’re licensed out of Israel to do R&D with cannabinoids, and we’ve kind of taken on a big mission and written a patent around high throughput screening and cancer and cannabinoids. So what we discovered a few years back is that actually, when we studied cannabinoids, they had a different effect – different combinations of cannabinoids had different effects on different cancers in different people. And that got us very curious, and we’re about to finalize the building out of our lab out here in Israel to study that and collect Big Data on the various combinations, and come out with both the diagnostic tools and treatments for cancer.

James West:   Fascinating. Can I ask you –

Ed Milewski:  Yeah, that is. That’s something.

James West:   What kind of cancers have cannabinoids demonstrated some efficacy for?

Eyal Barad:   Well, most of the cancers that we’ve actually studied have shown some sort of efficacy when properly applied and the right combinations have been applied to it. Once again, this is in the lab that we were doing on salines; afterwards, we moved into kind of testing it on circulating tumour cells that we’re extracting from blood samples, and that seems to be giving us similar indications. So we’re continuing our research and developing out our line of products that we’re going to come out with, and continuing to collect a lot of data from different sources, including from the patients, and, you know, we’re seeing what’s going on right now obviously with the FDA approving the first cannabinoid-based drug that could be prescribed by doctors, which we find to be the biggest problem, because even where there are regulations and doctors are able to prescribe, they do not have enough data to know what they’re prescribing in cannabis. And we want to add that additional layer of data for practitioners to be able to make educated choices about their cannabis therapies.

James West:   Interesting. So what stage of FDA trials have been conducted with any cannabinoids at this point?

Eyal Barad:   Well we saw today, GW coming out with their epilepsy drug with CBD that was approved by the FDA, so that’s a big thing, and I think that will open the door for many other, you know, things, and basically medications that will come out for different indications, you know, as they’ve probably solved a lot of the issues of the toxicity and the safety issues. I believe that will open the door for more and more activity in that domain.

James West:   Interesting. So how much – you’re traded on the OTC under CNBX, correct?

Eyal Barad:   Correct.

James West:   And do you have a listing anywhere else in the world right now?

Eyal Barad:   Not right now. We are contemplating doing a dual listing maybe sometime in Canada, and we are contemplating other plays on up-listing at some point, but nothing to notify right now.

James West:   Yeah, so can you tell me, just from the perspective of an investor, how many shares outstanding, and how much capital has been raised to date?

Eyal Barad:   We have about 25 million shares outstanding currently, and we’ve raised about $4.5 million, $5 million to date.

James West:   Oh, that’s not bad at all.

Ed Milewski:  And what’s the current price approximately?

Eyal Barad:   It’s slightly under $1.00. So, you know, it’s $0.95, $0.96, somewhere around there.

James West:   Interesting. So how does this, and at what point does this, make money, Eyal?

Eyal Barad:   Well, I tell you: we have, looking at diagnostics, where we’ve understood that even healthy people over the age of 40 have circulating tumour cells in their blood. So we’re considering actually commercializing further our diagnostic testing. We’re looking at coming out with, I mean, we’re currently licensed one of our products, which is a slow-release capsule, to one of our partners in Colorado; but continuing to think about developing other palliative, I’d say, products for the cancer market.

James West:   Okay. How long do you think it will be before you can actually get a product to market?

Eyal Barad:   Well, like I said, we already have one product to market, which we kind of tested the grounds very early on. It was a 50/50 product, so as we move more into the precision medicine domain, we look to kind of focalize more and come out with more precise products for specific people. But I think as we roll out, like I said, we are commercialized in a certain way, but we will continue to roll out stuff over time that will be money-making products.

Ed Milewski:  Eyal, what percentage of the shares are controlled by insiders and friends of insiders? Shares outstanding, 25 million; how many shares do you own, for instance?

Eyal Barad:   Well, I don’t own directly any shares; I own shares through a holding company that’s called Cannabics, Inc., and I own a good chunk of those shares. But we are a pretty big group over there, holding shares. Yeah.

James West:   Okay, great. Eyal, so are you going to be conducting tests in strictly Israel and the US, or will you expand to other countries as well?

Eyal Barad:     No, we’re actually looking at Germany very much. We have a partner in Germany right now that is doing some of our CTC, our circulating tumour cell, counts on our behalf that we’ve done out there. So we’re looking at the German market as well; it’s a strong market that Canadian products are also there. Canada is very interesting to us, and we have other outreaching with a number of other countries as well. As regulation, I guess, in different Federal-regulated states comes out, we’ll be reaching out to more and more countries.

James West:   Okay, great. Eyal, that’s a fantastic introduction. We’re going to leave it there and come back to you in a quarter’s time. Thanks very much for your time today.

Eyal Barad:   Thank you. Thank you for having me on.

More Great Cannabis Content

MidasLetter Live

Midas Letter LIVE!

Midas Letter LIVE is the video channel from Midas Letter Financial Group's headquarters studio in the Exchange Tower in the heart of Canada's Financial District in downtown Toronto, Ontario, where we interview the CEO's from the top emerging companies on the Canadian publicly traded company landscape. Live Streaming on Facebook...
More Info...

[email protected]

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!